Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Multiplex RNAscope ISH for Quantifying Transgene Expression in Gene Therapy Studies for EMA Submissions

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Multiplex RNAscope ISH for Quantifying Transgene Expression in Gene Therapy Studies for EMA Submissions

Multiplex RNAscope ISH for Quantifying Transgene Expression in Gene Therapy

CELL & GENE | RNA | BIOLOGICS

For AAV and other vector-based gene therapies, European Medicines Agency (EMA) submissions require robust, quantitative data demonstrating transgene expression within the intended target tissues. Multiplex RNAscope in situ hybridization (ISH) provides this evidence with single-cell resolution, directly visualizing and quantifying transgene mRNA in the context of complex tissue architecture. This technique is fundamental for confirming the mechanism of action, assessing expression durability, and de-risking regulatory filings by generating a definitive, spatially resolved dataset.

    What is Multiplex RNAscope ISH?

    A: It is a highly sensitive and specific in situ hybridization technique that enables the simultaneous visualization and quantification of multiple RNA targets within morphologically intact tissue sections.

    Why is this method preferred for EMA gene therapy submissions?

    A: The EMA requires precise data on transgene expression and localization. RNAscope ISH provides quantitative, single-cell resolution data, demonstrating which specific cell types are expressing the transgene, a key expectation for confirming the mechanism of action.

    How does RNAscope ISH differ from qPCR or mass spectrometry?

    A: RNAscope reveals spatial context. It shows which specific cells express the transgene and at what level, while bulk methods like qPCR or mass spectrometry provide an average measurement across the entire heterogeneous tissue sample, losing all cellular detail.

    Can this assay be run under GxP conditions?

    A: Yes. The entire workflow, from probe validation and tissue processing to image analysis and reporting, can be fully validated and executed within a GxP framework to generate a data package suitable for regulatory review.

The Regulatory Requirement for Quantitative Expression Data

Demonstrating durable and cell-type-specific transgene expression is a core requirement for advancing a gene therapy program toward clinical evaluation in Europe. Regulatory bodies expect to see definitive evidence that the therapeutic construct is being expressed in the correct anatomical location and within the intended cellular targets. This data forms the foundation of the efficacy and safety narrative in any submission.

Sustained expression is a primary determinant of long-term therapeutic benefit. As demonstrated in AAV gene therapy clinical trials, achieving stable transgene expression is a viable clinical endpoint, even when host immune responses to the vector capsid are detected (PMID: 19706466). This finding underscores the need for highly sensitive assays that can accurately monitor expression levels over the course of long-term preclinical studies.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Achieving Cellular Resolution with Multiplex ISH

Multiplex RNAscope ISH directly addresses the need for spatially resolved expression data. By designing probes specific to the transgene mRNA and co-staining with markers for distinct cell populations, we can precisely map expression patterns within a tissue. This approach moves beyond simple confirmation of presence or absence to deliver quantitative insights.

The advantages of this methodology include:

  • Cell-Specific Localization: Identify which cell types are expressing the transgene.

  • Quantitative Analysis: Utilize digital pathology and AI-powered algorithms to count mRNA transcripts on a per-cell basis.

  • Biodistribution Assessment: Evaluate expression in both target organs and in studies of non-target tissue biodistribution.

  • Correlation with Histology: Directly overlay expression data with standard histological assessments on the same tissue section to link expression with phenotype.

Quantitative Data for Biodistribution and Efficacy Studies

A comprehensive regulatory package for a gene therapy requires a dual demonstration: high-level, specific expression in target tissues (efficacy) and minimal or absent expression in non-target tissues (safety). Multiplex RNAscope ISH is uniquely suited to provide quantitative data for both aspects of the biodistribution profile.

For on-target efficacy, the assay can quantify the number of mRNA transcripts per cell within the desired cell population, confirming the intended biological activity. This spatially-resolved data provides direct evidence of the mechanism of action, linking vector administration to functional expression at the site of disease.

For safety and non-target tissue biodistribution assessments, the technique’s high sensitivity can detect even low levels of ectopic expression. By co-localizing transgene signals with cell-type-specific markers in non-target organs, it is possible to definitively determine which, if any, off-target cells are expressing the construct. This level of detail is difficult to achieve with bulk homogenization methods and provides regulators with greater confidence in the therapy’s safety profile.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

From Assay Development to a Submission-Ready Data Package

A successful RNAscope ISH study combines rigorous scientific oversight and technical execution within a GxP-compliant framework. Our process begins with custom assay development and validation tailored to your specific vector construct and tissue matrices. This is particularly important as accurately quantifying therapeutic expression often requires developing novel, highly sensitive methods, a principle validated in studies quantifying protein from AAV-delivered transgenes in complex tissues (PMID: 37891254).

All studies are conducted in our >100,000 sq ft facility, ensuring consistent, high-quality data generation from tissue processing through final reporting. By embedding these advanced pathology services within the preclinical timeline, we help sponsors build a comprehensive data package that supports an accelerated 18-24 month IND timeline. This integrated approach provides the rapid pathology insights accelerating preclinical readouts needed to make key program decisions. It is this commitment to quality and regulatory alignment that has supported our clients’ 100% IND success rate since 2019, with the Franklin Biolabs brand itself having launched in 2024.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities